NASDAQ: CORV TSX: CORV
Conference Call Scheduled for Tuesday,
August 14, 2018 at 4:30 p.m. Eastern
(1:30 p.m. Pacific)
VANCOUVER, Aug. 7, 2018 /PRNewswire/ - Correvio Pharma Corp.
(NASDAQ: CORV / TSX: CORV), a revenue-generating, specialty
pharmaceutical company focused on commercializing hospital drugs,
today announced that it will report financial results for the
second quarter ended June 30, 2018 on
Tuesday, August 14, 2018. Correvio
will hold a conference call and webcast at 4:30 p.m. Eastern (1:30
p.m. Pacific) on that day to discuss the results.
To access the conference call, please dial 416-764-8688 or
888-390-0546 and use conference ID 12980324. The
webcast can be accessed through the following link:
https://event.on24.com/wcc/r/1806440/C0B9D6FC0E2132792B5ECB68F02E7308
Webcast and telephone replays of the conference call will be
available approximately two hours after the completion of the call
through August 28, 2018. Please dial 416-764-8677 or
888-390-0541 and enter code 980324 # to access the replay.
About Correvio Pharma Corp.
Correvio Pharma Corp. is a revenue-generating, specialty
pharmaceutical company focused on providing innovative,
high-quality brands that meet the needs of acute care physicians
and patients. With a commercial presence and distribution network
covering over 60 countries worldwide, Correvio develops, acquires
and commercializes brands for the in-hospital, acute care market
segment. The Company's portfolio of approved and marketed brands
includes: Xydalba™ (dalbavancin hydrochloride), for the
treatment of acute bacterial skin and skin structure infections
(ABSSSI); Zevtera®/Mabelio® (ceftobiprole
medocaril sodium), a cephalosporin antibiotic for the treatment of
community- and hospital-acquired pneumonia (CAP, HAP);
Brinavess® (vernakalant IV) for the rapid conversion of
recent onset atrial fibrillation to sinus rhythm;
Aggrastat® (tirofiban hydrochloride) for the reduction
of thrombotic cardiovascular events in patients with acute coronary
syndrome, and Esmocard® and Esmocard Lyo®
(esmolol hydrochloride), a short-acting betablocker used to control
rapid heart rate in a number of cardiovascular indications.
Correvio's pipeline of product candidates includes
Trevyent®, a drug device combination that is designed to
deliver treprostinil, the world's leading treatment for pulmonary
arterial hypertension. Correvio is traded on the NASDAQ Capital
Market (CORV) and the Toronto Stock Exchange (CORV). For more
information, please visit our web site www.correvio.com.
Correvio® and the Correvio Logo are the proprietary
trademarks of Correvio Pharma Corp.
Aggrastat® and Brinavess® are trademarks
owned by Correvio and its affiliates worldwide.
Xydalba™ is a trademark of Allergan Pharmaceuticals
International Limited, and used under license. Zevtera®
and Mabelio® are trademarks owned by Basilea
Pharmaceutica International Ltd., and used under license.
Esmocard® and Esmocard Lyo® are trademarks
owned by Orpha-Devel Handels und Vertriebs GmbH, and used under
license.
Trevyent® is a trademark of SteadyMed Therapeutics, Inc.
and used under license.
All other trademarks are the property of their respective
owners.
View original
content:http://www.prnewswire.com/news-releases/correvio-to-report-second-quarter-2018-financial-results-on-august-14-2018-300691875.html
SOURCE Correvio Pharma Corp